Drugs / Human Interleukin-11
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT07185893 Comparator | Sep 2025 → Mar 2028 expected | cancer, thrombocytopenia | Jun Wang | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Interleukin-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07185893 ↗ |
| Known as | rhlL-11 | “Human Interleukin-11 for Injection (rhlL-11) 25 - 50 μg/kg, subcutaneous injection, once a day, for at least 7 - 10 days.” NCT07185893 ↗ |
| Route | Subcutaneous | “Human Interleukin-11 for Injection (rhlL-11) 25 - 50 μg/kg, subcutaneous injection, once a day, for at least 7 - 10 days.” NCT07185893 ↗ |